Dr Hans Klingemann
Vice President of R&D, NantKwest, Inc
Dr. Klingemann is currently VP of Research and Development at NantKwest (NASDAQ: NK), the company he founded in 2002 as ZelleRx based on the core technology of NK-92. He is the former Director of the Bone Marrow and Stem Cell Transplant Program at Boston’s Tufts Medical Center and the Cancer Center’s Hematological Malignancies Program. Before coming to Boston, Dr. Klingemann served as Director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center in Chicago, and was the founding Director of the Sramek Center for Cell Engineering. He has worked as physician, scientist, educator, and administrator in leadership positions for more than 25 years at various academic medical centers in Europe, Canada and the United States and has authored over 170 scientific and medical papers. He maintains a professorship at Tufts Medical Center.